TRANSVAC October Newsletter is out!

Updated: Feb 18

TRANSVAC Training Modules đź“–

OPEN CALL | Submit your application for TRANSVAC Courses now


M4 Validity and translational aspects of animal models in vaccine research

In brief: This course is designed to critically discuss the design of animal studies: choice of animal models, presentation of less frequently used animal species, animal numbers and the extrapolation of results to humans.

Where? Wageningen University, The Netherlands

When? 12-13 March 2020


M6 Cytometry by time of flight CyTOF

In brief: Cytometry by time of flight (CyTOF) or mass cytometry allows the simultaneous detection of multiple phenotypic markers at the single cell level. You can learn a theory and practice of mass-cytometry applied to assessing the immune response in human and animal models.

Where? CEA, France

When? 4-5 March 2020


M8 In vivo Imaging

To be introduced to multimodal in vivo imaging from the basic principles including basics in biophysics, methodologies for in vivo imaging, to image analysis and biological interpretation of the results.

Where? CEA, France

When? 2-4 March 2020

⏳ Apply here until November 15th, 2019


TRANSVAC Vaccine Development Services 🧪

OPEN CALL | Submit your application for TNA services now


TRANSVAC2 project offers high-quality technical services to support the development of prophylactic and therapeutic vaccines for both human and animal use.

- These services are not restricted to any disease in particular.

- Services will be offered free of charge, with few exceptions!

- Academic and non-academic research groups, SMEs and industries can apply but only to service infrastructures outside their own country.


Check out TRANSVAC services >>>


⏳ Apply here until December 15th, 2019



đź“Ł New partnership with ERINHA-Advance allows TRANSVAC users to apply with projects studying highly infectious pathogens.



The first TNA Call to ERINHA’s full catalogue of services, including access to cutting‑edge high‑containment facilities was also launched on October 15th, 2019.

The following pathogens are prioritized within this call: Ebola virus, Marburg virus, Lassa virus, Crimean‑Congo Hemorrhagic Fever virus and Nipah virus.


Applicants with interest in highly pathogenic agents and vaccine development are encouraged to apply to both calls. More info >>>


CHECK OUR PARTNERS

The Vaccine Development Department at SSI is responsible for a wide range of tasks including development of manufacturing processes for new biological products and adjuvants; formulation and analysis development, and manufacturing of products for clinical trials. For more details visit the Vaccine Development Department and Vaccine Adjuvant research webpages.




This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement N° 730964.

Be the first to know about the upcoming application calls, follow European Vaccine Initiative on:

  • LinkedIn Social Icon
  • Twitter Social Icon
Subscribe to TRANSVAC´s Mailing list

© 2020 European Vaccine Initiative. Designed by European Vaccine Initiative